<DOC>
	<DOCNO>NCT02039076</DOCNO>
	<brief_summary>This randomize , open-label , 5-treatment-period study evaluate PK PD avatrombopag follow single administration avatrombopag feed fasted condition , feed condition , healthy Japanese white subject . A standard high-fat , high calorie breakfast use ass feed condition .</brief_summary>
	<brief_title>A Five-Treatment-Period Study Evaluate Single-Dose Pharmacokinetics Pharmacodynamics Avatrombopag Healthy Japanese White Subjects</brief_title>
	<detailed_description>The study comprise Prerandomization Phase Randomization Phase . The Prerandomization Phase include 2 period , Screening Baseline 1 . The Screening Period 3 week ( 21 day ) duration . The Randomization Phase consist 5 single-dose treatment period , 3 include administration avatrombopag feed condition 2 include administration avatrombopag fasted condition . Each treatment period separate wash interval least 28 day . Before treatment period , subject complete baseline period ( Baseline Periods 2 , 3 , 4 , 5 ) , baseline assessment collect . A Final Visit occur 28 day ( +/- 1 day ) dose Treatment Period 5 .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Inclusion Criteria 1 . Platelet count lower limit normal 350 x 109/L , inclusive , Screening Baseline ; measurement repeat verification , necessary 2 . Nonsmoking , healthy white Japanese adult male female subject , great equal 20 year less equal 55 year old time inform consent . ( Nonsmokers define discontinue smoke least 4 week dose . ) 3 . Japanese subject must bear Japan Japanese parent Japanese grandparent , must live 5 year outside Japan , must change lifestyle habit , include diet , live outside Japan . 4 . Body mass index great equal 18 less equal 28 kg/m2 Screening Baseline Period 1 . The BMI white subject must within +/ 2 kg/m2 BMI Japanese subject . 5 . Nonsmoking , healthy white Japanese adult male female age 20 55 , inclusive 6 . BMI 18 28. inclusive 7 . Females must pregnant lactating , childbearing potential must agree use highly effective method contraception abstain 8 . Males must vasectomy partner must use highly effective method contraception Exclusion Criteria 1 . Evidence organ dysfunction clinically significant deviation normal medical history ( eg , history splenectomy ) ; history arterial venous thrombosis , include partial complete thromboses ( eg , stroke , transient ischemic attack , myocardial infarction , deep vein thrombosis , pulmonary embolism ) ; know family history hereditary thrombophilic disorder ( eg , Factor V Leiden , antithrombin III deficiency ) 2 . Recent clinically significant illness infection require medical treatment 3 . Evidence disease may influence outcome study ( eg , psychiatric disorder , disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system ) , subject congenital abnormality metabolism 4 . Any history gastrointestinal surgery ( eg , hepatectomy , nephrotomy , digestive organ resection ) 5 . Any clinically abnormal symptom organ impairment find medical history , physical examination , vital sign electrocardiogram ( ECG ) assessment , laboratory test result 6 . A known suspected history drug alcohol dependency abuse positive urine drug , cotinine , alcohol test 7 . Positive result human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody Screening 8 . Weight loss gain &gt; 10 % within 4 week dose 9 . Known history clinically significant drug food allergy 10 . Currently enrol another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Healthy</keyword>
</DOC>